Clinical trial · Interventional
Open Label, Phase I ZD6474 Head and Neck Cancer Study
An Open Label Phase 1 Study to Assess the Maximum Tolerated Dose of ZACTIMA™ Given Concomitantly With Weekly Cisplatin Chemotherapy and Radiation Therapy in Patients With Previously Untreated, Unresected Stage III-IV Head and Neck Squamous Cell Carcinoma
NCT00450138CI-TRIAL-00023674completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the maximum tolerated dose of ZD6474 given in combination with radiation or in combination with chemotherapy and radiation in patients with squamous cell carcinoma of the head and neck.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cisplatin | Drug | Cisplatin | ALIAS |
| Radiation | Radiation | — | UNRESOLVED |
| ZD6474 (vandetanib) | Drug | Vandetanib | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1
- description
- Radiation + vandetanib
- interventionNames
- Drug: ZD6474 (vandetanib)
- Radiation: Radiation
- type
- EXPERIMENTAL
- label
- 2
- description
- Radiation + cisplatin + vandetanib
- interventionNames
- Drug: ZD6474 (vandetanib)
- Drug: Cisplatin
- Radiation: Radiation
Primary outcomes (1)
- measure
- To determine the maximum tolerated dose of vandetanib given in combination with radiation or radiation and chemotherapy in patients with late stage head and neck cancer
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Stage III-IV squamous cell carcinoma of the head and neck Exclusion Criteria: * No previous treatment for head and neck cancer, adequate cardiac function
References
Publications (0)
Data not yet available
No reference posted for this study.